Pfizer : Q1 2024 Financial Quarterly Report : YoY Sales Up 5.93 %, QoQ Up 2.97 %

The comprehensive analytics outlining the performance and outlook of Pfizer Limited”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at Pfizer Limited’s financial performance for the Q1(Jun 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 5.93 %. However, it did see a marginal increase of 2.97 % from the previous quarter. Expenses ticked up slightly by 7.89 % quarter-on-quarter, aligning with the annual decline of -8.39 %. Operating profit, while up 60.32 % compared to last year, faced a quarter-on-quarter dip of -6.3 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 10.69 %, but a shrinkage of -3.12 % sequentially. Other income fell by -44.31 % compared to the last quarter, despite an annual growth of 25.04 %. Interest expenses dropped significantly by -69.64 % from the previous quarter, yet the year-over-year decrease remains at a moderate -26.48 %. Depreciation costs climbed by 6.18 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -6.11 %. Profit before tax grew annually by 61.13 % but saw a reduction from the preceding quarter by -16.91 %.
Tax expenses as a percentage of profits increased slightly by 0 % compared to last year, with a more notable quarter-on-quarter decrease of -1.03 %. Net profit rose by 61.14 % year-on-year but witnessed a -15.74 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 61.15 % but a quarterly rise of 47.51 %. In summary, Pfizer Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Pfizer Limited’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 5.93 % year-on-year growth, however, there was a minor increase of 2.97 % from the previous quarter. Expenses decreased by -8.39 % compared to the previous year, with a 7.89 % increase quarter-on-quarter. Operating Profit surged by 60.32 % annually, and saw a -6.3 % decrease from the last quarter.
Net Profit showed yearly increase of 61.14 %, and experienced a -15.74 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 61.15 % annually, however rose by 47.51 % compared to the last quarter. In essence, while Pfizer Limited exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.